Modified Gliadin Peptide IgG EULISA

Add to my product list
Celiac disease (CD) is caused by a hypersensitivity reaction of genetically predisposed individuals to ingested gluten. Elevated levels of gliadin-specific antibodies occur in the sera of celiac patients. The EULISA Modified Gliadin Peptide IgG is intended for the determination of such IgG antibodies in human serum.

Product code
215096
Format
ELISA
Tests
Break apart micro titration strips (12x8) 96 wells
Calculation
Qualitative or qualitative
Antigen
Modified gliadin peptide (MGP)
Units
U/mL
Calibrators
6
Range
0-100 U/mL
Incubation time
30+30+30 min
Detection system
HRP/450 nm
Availability
CE marked. Not for sale in US

Intended use

Enzyme immunoassay for the detection of autoantibodies IgG against modified gliadin peptide (MGP)

Background

Celiac disease (CD) is caused by a hypersensitive reaction of genetically predisposed individuals to ingested gluten. Gluten is a set of proteins present in many kinds of cereal grain, e.g. wheat, barley and rye. CD affects the upper small intestine and results in more or less complete atrophy of the villi of the mucous membrane which can lead to malabsorption problems, e.g. chronic vitamin deficiency. The symptoms are variable or sometimes even absent.

Elevated levels of gliadin-specific antibodies occur in the sera of celiac patients. Gliadin is a component of gluten and constitutes a predominant antigen. It is fragmented in the small intestine and the resulting peptides are deamidated by the enzyme tissue transglutaminase (tTG) which itself has been identified as the major CD autoantigen.

Recently, it was shown that certain deamidated gliadin peptides are powerful immunogens and that antibodies directed at these peptides exhibit a better diagnostic accuracy for CD, as compared to antibodies directed at crude gliadin.

Technical information

The EULISA Modified Gliadin Peptide IgG is intended for the quantitative or qualitative determination of IgG antibodies in human serum, directed against a modified (deamidated) gliadin peptide (MGP). The immobilised antigen is a highly purified, synthetic peptide derivative. The test is fast (incubation time 30-30-30 minutes) and flexible (break apart wells, ready-to-use reagents). Six calibrators allow quantitative measurements; a negative and a positive control are used to check assay performance.

Kit components and storage of reagents

Contents of the kit

  1. One microwell plate, coated with MGP and hermetically packed in a foil laminate pouch together with a desiccant bag.
  1. Sample buffer, 100 mL, ready-to-use, orange coloured.
  1. Wash buffer, 100 mL, 10 x-concentrate, blue coloured.
  1. 6 calibrators, 2.0 mL each, 0, 3.0, 8.0, 18, 45 and 100 U MGP antibodies IgG/mL, ready-to-use, gradually blue coloured.
  1. Negative and positive control, 2.0 mL each, ready-to-use, green and red coloured, respectively.
  1. Anti-human IgG HRP conjugate, 14 mL, ready-to-use, red coloured.
  1. Substrate solution, 14 mL, ready-to-use, colourless.
  1. Stop solution (0.5 M H2SO4), 14 mL, colourless, ready-to-use.
  1. Directions for use
  1. Lot-specific certificate of analysis

All kit components are stored at 2 - 8°C.